AMGN

Business profile & competitive position

Amgen Inc. is classified in the Healthcare sector, within the Drug Manufacturers - General industry. According to its most recent 10-K, the company discovers, develops, manufactures and delivers innovative human therapeutics targeting serious diseases and areas of high unmet medical need. It describes itself as one of the world’s leading independent biotechnology companies, with a commercial presence in approximately 100 countries and a single operating segment focused on human therapeutics.

The reported financial metrics—net margin of 22.9% and return on equity of 89.3%—fit a large, established biopharma model built around differentiated biologics and operating leverage. A 22.9% net margin means Amgen retains roughly $0.23 of every revenue dollar after all expenses, while an 89.3% ROE indicates equity capital has historically generated very high returns. Investors should remember that an elevated ROE can also reflect financial leverage as well as underlying profitability, so it is best read alongside the balance sheet rather than as a standalone moat measure.

The 10-K also highlights customer concentration: three wholesalers accounted for 77% of worldwide gross revenues in 2025. With U.S. product sales of $25.7 billion (73% of total) and rest-of-world sales of $9.5 billion (27%), Amgen remains heavily U.S.-weighted and dependent on a small number of distribution partners.

Competitive dynamics are shifting. U.S. and select European patents for Prolia/XGEVA expired in 2025, and Amgen explicitly expects accelerated sales erosion as multiple biosimilars launch. At the same time, the company has launched eight biosimilars since 2018, including U.S. introductions of WEZLANA and BKEMV in 2025, showing it is competing on both the innovator and biosimilar sides of the market.

Financial posture

Amgen’s market capitalization stands at $233.1 billion, and the stock was trading at $431.16 at the time of the snapshot, for a trailing P/E ratio of 26.6. The beta of 0.41 signals that the shares have historically moved less than half as much as the broader equity market, a profile typical of large-cap defensive healthcare names with recurring prescription demand.

Pairing a 22.9% net margin with an 89.3% ROE frames Amgen as one of the more profitable large-cap healthcare companies. The P/E of 26.6 prices in continued earnings resilience, but that valuation is being actively debated. A 2026-10-19 GuruFocus headline asked “Is AMGN Overvalued? DCF Says Worth $189,” citing a discounted-cash-flow value well below the current market price. That headline is an external data point, not this platform’s view, and it illustrates why some market participants are scrutinizing the gap between trailing valuation and model-based estimates.

Technically, AMGN’s RSI was 62.4, modestly above mid-range but not in overbought territory, and the price was above its 50-day exponential moving average of $407.86.

Strategic priorities & outlook

Amgen’s most recent 10-K outlines four near-term operational priorities. First, it aims to expand the approved disease areas and indications for its marketed products, extending the commercial runway of existing assets. Second, it wants to find new methods to make the delivery or manufacture of medicines easier and less costly, an efficiency push that helps protect margins as pricing pressure builds. Third, it continues to pursue innovation to differentiate products and strengthen competitive position, especially as biosimilar alternatives enter its core markets. Fourth, it plans to leverage its global scale and experience to distinguish itself against both branded rivals and biosimilar competitors.

These priorities line up with the data already cited: expanding indications for a portfolio facing patent expiry is a logical response to Prolia/XGEVA’s 2025 patent losses, and the emphasis on manufacturing cost reduction fits a business confronting accelerated sales erosion. The biosimilar launches—WEZLANA and BKEMV in the U.S. in 2025—illustrate a strategy to capture value on the generic-biologic side while the innovator franchise matures.

Macro & geopolitical exposure

As a Drug Manufacturers - General company, Amgen is exposed to macro and policy risks inherent in the global pharmaceutical industry rather than to commodity or cyclical industrial cycles. The most direct levers include FDA and EMA regulatory decisions, patent law and exclusivity periods, drug-pricing legislation, reimbursement pressure from Medicare and private payers, and currency translation effects on international revenue.

The 10-K’s rest-of-world sales share of 27% means foreign-exchange movements against the U.S. dollar can affect reported growth even if local-currency demand is stable. Trade policy, including tariffs on imported active pharmaceutical ingredients or finished goods, can also reshape cost structures for a global manufacturer. Recent headlines, such as the 2026-10-19 GuruFocus “First Look” noting Iran War-driven oil prices, AI-stock volatility, and France’s debt crisis, served as a reminder that geopolitical risk can spill into broader market sentiment and risk assets, even if a large biopharma company is not directly tied to oil or AI.

Customer concentration—three wholesalers representing 77% of worldwide gross revenues—adds another operational dimension. Changes in wholesaler inventory levels or payer reimbursement negotiations can translate into meaningful quarter-to-quarter revenue volatility.

Recent developments

The most recent news flow around AMGN, captured on 2026-10-19, included a Zacks.com article headlined “Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know.” The same day, GuruFocus published two pieces: one asking “Is AMGN Overvalued? DCF Says Worth $189,” and a broader market roundup on Iran War-driven oil prices, AI-stock volatility, and France’s debt crisis. One day earlier, on 2026-10-18, Seeking Alpha featured “The Winners Inside SCHD - October 2026,” suggesting AMGN remains on the radar of dividend-focused ETF investors.

Taken together, these headlines underscore two themes: elevated investor attention to Amgen’s current valuation, and the wider macro backdrop against which defensive healthcare names are being evaluated. None of the headlines report company-specific operational changes, but the valuation discussion reinforces that market participants are actively debating whether the current P/E of 26.6 is supported by fundamentals.

Earnings behavior & post-earnings drift

Amgen’s earnings track record over the past eight quarters is unblemished: it beat analyst estimates in all eight periods, with an average earnings surprise of 10.9%. The average five-day price move following those reports has been +5.76%, classified as an upward post-earnings drift.

The last four quarters, most recent first, show the pattern in detail. On 2026-08-04, Amgen reported EPS of $6.29 versus a $5.62 estimate—an 11.9% surprise—and the stock rose 4.57% the next day and 6.23% over the following five sessions. On 2026-04-30, actual EPS came in at $5.15 against a $4.77 estimate (an 8.0% surprise), yet the market reaction was negative, with the stock falling 4.75% the next day and 4.96% over the next five days. On 2026-02-03, EPS of $5.29 beat the $4.73 estimate by 11.8%, driving an 8.15% one-day gain and a 7.7% five-day gain. Finally, on 2025-11-04, EPS of $5.64 topped the $5.02 estimate by 12.4%, producing a 7.81% next-day move and a 14.07% five-day move.

The next scheduled report is on 2026-11-03 after the market close, with a consensus EPS estimate of $5.77. The 100% beat rate establishes a consistent pattern of realized results exceeding analyst models, but it does not guarantee any future outcome. The upcoming print will likely be judged against guidance commentary on Prolia/XGEVA biosimilar erosion and newer biosimilar revenue contributions, both of which were flagged in the 10-K.

For a deeper dive into how institutional analysts are positioning Amgen ahead of the November 2026 earnings report, review the full institutional verdict on the company’s page.